Valuation: IO Biotech, Inc.

Market Cap 43.81M 38.53M 35.79M 32.92M 61.74M 4.24B 62.84M 428M 167M 2.07B 164M 161M 7.18B P/E 2023
-0.95x
P/E 2024 -0.63x
Enterprise Value -14.31M -12.58M -11.69M -10.75M -20.16M -1.39B -20.52M -140M -54.52M -676M -53.71M -52.55M -2.34B EV / Sales 2023
-
EV / Sales 2024 -
Free-Float
99.69%
Yield 2023 *
-
Yield 2024 -
1 day-67.74%
1 week-83.33%
Current month-83.61%
1 month-87.50%
3 months-82.76%
6 months-99.73%
Current year-99.84%
1 week 0
Extreme 0.0002
0.01
1 month 0
Extreme 0.0002
0.01
Current year 0
Extreme 0.0002
0.7
1 year 0
Extreme 0.0002
2.79
3 years 0
Extreme 0.0002
2.79
5 years 0
Extreme 0.0002
17.88
10 years 0
Extreme 0.0002
17.88
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/10/2021
Compliance Officer 58 23/01/2023
Investor Relations Contact - 01/04/2023
Date Insider Type Main position Quantity % Market Cap.
6/5/25 A Free

Director

35,144 0.0533%
6/5/25 A Free

Director

35,144 0.0533%
6/5/25 A Free

Director

35,144 0.0533%
Change 5-day change 1-year change 3-year change Capi.($)
-67.74%-83.33%-99.95%-99.95% 71.95K
+1.08%-5.74%-4.98%+10.45% 46.35B
+3.13%+5.34%+402.93%+605.08% 40.13B
+2.14%+2.95%+10.83%+65.45% 36.33B
+4.43%-1.51%+6.73%-9.17% 34.6B
+1.23%-2.05%+0.56%+30.76% 26.77B
+0.29%-2.75% - - 16.66B
+14.71%+12.62%+38.50%+146.99% 16.91B
-6.32%-4.86%+4.36%+8.22% 13.05B
+1.82%+0.19%+1.45%-30.74% 13.05B
Average -4.67%+0.42%+40.05%+80.79% 24.38B
Weighted average by Cap. +2.36%+0.23%+76.18%+131.35%

Financials

2023 2024
Net sales - -
Net income -86.08M -75.71M -70.33M -64.69M -121M -8.34B -123M -841M -328M -4.07B -323M -316M -14.11B -95.49M -83.98M -78.02M -71.76M -135M -9.25B -137M -933M -364M -4.51B -358M -351M -15.65B
Net Debt -141M -124M -115M -106M -198M -13.63B -202M -1.37B -536M -6.65B -528M -517M -23.06B -58.12M -51.11M -47.48M -43.67M -81.9M -5.63B -83.37M -568M -221M -2.75B -218M -213M -9.52B
Logo IO Biotech, Inc.
IO Biotech Inc is a clinical-stage biopharmaceutical company developing immune-modulating cancer therapies based on T-win technology platform. The Company’s product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. IO Biotech’s lead product candidate, IO102-IO103, is designed to target the immunosuppressive mechanisms mediated by key immunosuppressive proteins such as IDO and PD-L1. The Company develops a pipeline of product candidates that leverage its T-win technology platform to address targets within the TME. The Company is spin-off of National Cancer for Center Immune Therapy at Herlev University Hospital in Denmark.
Employees
80
Date Price Change Volume
22/07/26 $0.001000 -67.74% 16,666
20/07/26 $0.003100 -43.64% 431,318
17/07/26 $0.005500 -8.33% 29,903
16/07/26 $0.006000 +20.00% 1,144,948
15/07/26 $0.005000 -15.25% 278,333

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. IOBTQ Stock